journal article·2022-07-27

Protein’s Protein Corona: Nanoscale Size Evolution of Human Immunoglobulin G Aggregates Induced by Serum Albumin

Tomohito Nakayama, Kaito Kobayashi, Tomoshi Kameda, Muneaki Hase, Atsushi Hirano

ACS Applied Materials & Interfaces· Volume 14· Issue 29
Publisher page

Abstract

Nanoparticles are readily coated by proteins in biological systems. The protein layers on the nanoparticles, which are called the protein corona, influence the biological impacts of the nanoparticles, including internalization into cells and cytotoxicity. This study expands the scope of the nanoparticle’s protein corona for exogenous artificial nanoparticles to that for exogenous proteinaceous nanoparticles. Specifically, this study addresses the formation of protein coronas on nanoscale human antibody aggregates with a radius of approximately 20–40 nm, where the antibody aggregates were induced by a pH shift from low to neutral pH. The size of the human immunoglobulin G (hIgG) aggregates grew to approximately 25 times the original size in the presence of human serum albumin (HSA). This size evolution was ascribed to the association of the hIgG aggregates, which was triggered by the formation of the hIgG aggregate’s protein corona, i.e., protein’s protein corona, consisting of the adsorbed HSA molecules. Because hIgG aggregate association was significantly reduced by the addition of 30–150 mM NaCl, it was attributed to electrostatic attraction, which was supported by molecular dynamics (MD) simulations. Currently, the use of antibodies as biopharmaceuticals is concerning because of undesired immune responses caused by antibody aggregates that are typically generated by a pH shift during the antibody purification process. The present findings suggest that nanoscale antibody aggregates form protein coronas induced by HSA and the resulting nanoscale antibody–HSA complexes are stable in blood containing approximately 150 mM salt ions, at least in terms of the size evolution. Mechanistic insights into protein corona formation on nanoscale antibody aggregates are useful for understanding the unintentional biological impacts of antibody drugs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Protein purification and stability · Microfluidic and Bio-sensing Technologies · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Applied Physics, Faculty of Pure and Applied Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8573, Japan

Nanomaterials Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8565, Japan

Artificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Koto, Tokyo135-0064, Japan

Funding

Japan Society for the Promotion of Science

References (70)

Show source-provided references
1. 10.1021/acsnano.7b0800810.1021/acsnano.7b08008 ↗
2. 10.1073/pnas.110527010810.1073/pnas.1105270108 ↗
3. 10.1021/nn406101210.1021/nn4061012 ↗
4. 10.1016/j.biomaterials.2015.10.01910.1016/j.biomaterials.2015.10.019 ↗
5. 10.1039/c8nr03331e10.1039/c8nr03331e ↗
6. 10.1021/acs.biomac.9b0165010.1021/acs.biomac.9b01650 ↗
7. 10.1016/j.nantod.2020.10093710.1016/j.nantod.2020.100937 ↗
8. 10.1021/acsnano.8b0234610.1021/acsnano.8b02346 ↗
9. 10.1186/s12929-019-0592-z10.1186/s12929-019-0592-z ↗
10. 10.1016/j.addr.2016.11.00410.1016/j.addr.2016.11.004 ↗
11. 10.1089/blr.2013.992710.1089/blr.2013.9927 ↗
12. 10.1002/jps.2072710.1002/jps.20727 ↗
13. 10.4161/19420862.2015.98904210.4161/19420862.2015.989042 ↗
14. 10.1016/j.ijpharm.2011.12.03910.1016/j.ijpharm.2011.12.039 ↗
15. 10.1007/BF0083201010.1007/BF00832010 ↗
16. 10.3390/jcm803038710.3390/jcm8030387 ↗
17. 10.1111/jgh.1403410.1111/jgh.14034 ↗
18. 10.1111/jdv.1243810.1111/jdv.12438 ↗
19. 10.1016/j.ijpharm.2020.11952310.1016/j.ijpharm.2020.119523 ↗
20. 10.1016/j.ijpharm.2004.11.01410.1016/j.ijpharm.2004.11.014 ↗
21. 10.1016/j.ijpharm.2012.04.04010.1016/j.ijpharm.2012.04.040 ↗
22. 10.1007/s11095-016-1914-410.1007/s11095-016-1914-4 ↗
23. 10.1208/aapsj08035910.1208/aapsj080359 ↗
24. 10.1074/jbc.M111.33090210.1074/jbc.M111.330902 ↗
25. 10.1002/jps.2153010.1002/jps.21530 ↗
26. 10.4049/jimmunol.173.5.314810.4049/jimmunol.173.5.3148 ↗
27. 10.1103/PhysRevLett.53.140310.1103/PhysRevLett.53.1403 ↗
28. 10.1002/pro.30910.1002/pro.309 ↗
29. 10.1007/s11095-011-0416-710.1007/s11095-011-0416-7 ↗
30. 10.1074/jbc.M111.29769710.1074/jbc.M111.297697 ↗
31. 10.1021/jp301091n10.1021/jp301091n ↗
32. 10.1016/j.bpc.2012.12.00410.1016/j.bpc.2012.12.004 ↗
33. 10.1021/acs.jpcb.6b0547310.1021/acs.jpcb.6b05473 ↗
34. 10.1021/acs.analchem.8b0597910.1021/acs.analchem.8b05979 ↗
35. 10.1063/1.44873010.1063/1.448730 ↗
36. 10.1021/acs.analchem.6b0195810.1021/acs.analchem.6b01958 ↗
37. 10.1021/ac901258g10.1021/ac901258g ↗
38. 10.1248/bpb.28.159010.1248/bpb.28.1590 ↗
39. 10.1023/B:PHAM.0000029275.41323.a610.1023/B:PHAM.0000029275.41323.a6 ↗
40. Labrou N. E. · 201410.1007/978-1-62703-977-2 ↗
41. 10.1021/mp500759p10.1021/mp500759p ↗
42. 10.1016/j.jchromb.2006.09.02610.1016/j.jchromb.2006.09.026 ↗
43. 10.1016/j.ymeth.2011.10.00710.1016/j.ymeth.2011.10.007 ↗
44. 10.1080/02648725.2001.1064801710.1080/02648725.2001.10648017 ↗
45. 10.1016/bs.mie.2019.02.02110.1016/bs.mie.2019.02.021 ↗
46. 10.1021/bi100841u10.1021/bi100841u ↗
47. Minow B. · BioProcess Int. · 2012 · 10 · 48
48. Lütke-Eversloh T. · Pharm. Ind. · 2018 · 80 · 281
49. 10.1016/S0006-3495(00)76602-110.1016/S0006-3495(00)76602-1 ↗
50. 10.1073/pnas.150085111210.1073/pnas.1500851112 ↗
51. 10.1093/nar/gky49710.1093/nar/gky497 ↗
52. 10.1080/19420862.2017.129790910.1080/19420862.2017.1297909 ↗
53. 10.1073/pnas.111224110810.1073/pnas.1112241108 ↗
54. 10.1021/jp076348z10.1021/jp076348z ↗
55. 10.1016/j.ijbiomac.2017.10.00410.1016/j.ijbiomac.2017.10.004 ↗
56. 10.1039/C5SM00954E10.1039/C5SM00954E ↗
57. 10.1016/j.jbiotec.2018.10.00910.1016/j.jbiotec.2018.10.009 ↗
58. 10.1016/j.jim.2014.01.00310.1016/j.jim.2014.01.003 ↗
59. 10.1021/acs.langmuir.0c0347110.1021/acs.langmuir.0c03471 ↗
60. 10.1016/j.jaci.2009.09.04610.1016/j.jaci.2009.09.046 ↗
61. 10.1016/j.jmb.2012.11.01910.1016/j.jmb.2012.11.019 ↗
62. 10.1002/jps.2415710.1002/jps.24157 ↗
63. Jossang, T.; Feder, J.; Rosenqvist, E. Heat Aggregation of Human IgG A Dynamic Light Scattering Study. In Scattering Techniques Applied to Supramolecular and Nonequilibrium Systems; 1981; pp. 831–837.10.1007/978-1-4684-4061-4_48 ↗
64. 10.1038/s41565-018-0246-410.1038/s41565-018-0246-4 ↗
65. 10.1038/s41467-021-25584-610.1038/s41467-021-25584-6 ↗
66. 10.1371/journal.pone.002465710.1371/journal.pone.0024657 ↗
67. 10.1016/j.softx.2015.06.00110.1016/j.softx.2015.06.001 ↗
68. 10.1021/acs.jctc.5b0025510.1021/acs.jctc.5b00255 ↗
69. 10.1063/1.44586910.1063/1.445869 ↗
70. 10.1021/jp800161410.1021/jp8001614 ↗